Weiss Ashley, Dang Cathyyen, Mabrey Danielle, Stanton Matthew, Feih Jessica, Rein Lisa, Feldman Ryan
Froedtert & The Medical College of Wisconsin, Department of Pharmacy, Wisconsin.
The Medical College of Wisconsin, School of Pharmacy, Wisconsin.
Shock. 2021 Dec 1;56(6):988-993. doi: 10.1097/SHK.0000000000001830.
The optimal vasoactive agent for management of patients with return of spontaneous circulation (ROSC) after cardiac arrest has not yet been identified. The Advanced Cardiac Life Support guidelines recommend initiation of either norepinephrine (NE), epinephrine (EPI), or dopamine (DA) to maintain adequate hemodynamics after ROSC is achieved. The goal of this study is to retrospectively assess the impact of initial vasopressor agent on incidence rate of rearrest, death, or need for additional vasopressor in post-cardiac arrest emergency department (ED) patients.
A retrospective review of electronic medical records was conducted at a tertiary care, academic medical center over a 32-month period. Inclusion criteria were any patient who received vasopressors in the ED after achieving ROSC from out-of-hospital cardiac arrest, or in ED cardiac arrest. The incidence of the primary outcome was assessed during care within the ED, at 6 h regardless of location (early resuscitation period), and throughout the entire hospitalization. Secondary outcomes included incidence of tachyarrhythmia while on vasopressor, type of additional therapy needed for refractory shock, and functional status at discharge as determined by discharge location (discharged home without assistance, or discharged to long-term care facility, subacute rehabilitation, or assisted living).
A total of 93 patients were included for analysis; 45 received NE, 42 EPI, and six DA. Due to small sample size, DA was excluded from reporting post hoc. Significantly more EPI patients met the primary outcome of refractory hypotension, rearrest, or death in the emergency department (EPI 21/42, 50% vs. NE 10/45, 22.2%; P = 0.008). The incidence was no longer significantly different during the early resuscitation period of 6 h (EPI 30/42, 71.4% vs. NE 25/45, 55.6%; P = 0.182), or during the entire hospitalization (EPI 40/42, 95.2% vs. NE 36/45, 80.0%; P = 0.051). Notably, the EPI group had higher rates of rearrest prior to vasopressor initiation, potentially signaling more severe illness despite other prognostic variables being similarly distributed. In an adjusted regression model, which included adjustment for rearrest prior to vasopressor initiation, the odds of reaching the primary outcome in the ED were 3.94 [95%CI 1.38-12.2] (P = 0.013) times higher in the EPI group compared to NE treated patients. No difference in tachyarrhythmia or functional status at discharge was detected between groups.
These data suggest prospective study of initial vasopressors used for hemodynamic support after ROSC may be warranted. Rates of intra-emergency department refractory shock, rearrest, or death were higher among epinephrine treated patients compared to norepinephrine treated patients in this population. However, inability to control for potential confounding variables in retrospective studies limits the findings. These results are hypothesis generating and further study is warranted.
心脏骤停后自主循环恢复(ROSC)患者管理的最佳血管活性药物尚未确定。高级心脏生命支持指南建议在实现ROSC后开始使用去甲肾上腺素(NE)、肾上腺素(EPI)或多巴胺(DA)来维持足够的血流动力学。本研究的目的是回顾性评估初始血管升压药对心脏骤停后急诊科(ED)患者再次心脏骤停、死亡或需要额外血管升压药发生率的影响。
在一家三级医疗学术医学中心对32个月期间的电子病历进行回顾性研究。纳入标准为在院外心脏骤停或急诊科心脏骤停实现ROSC后在急诊科接受血管升压药治疗的任何患者。主要结局的发生率在急诊科护理期间、无论位置的6小时内(早期复苏期)以及整个住院期间进行评估。次要结局包括使用血管升压药期间快速性心律失常的发生率、难治性休克所需的额外治疗类型以及出院时的功能状态(无协助出院回家,或出院到长期护理机构、亚急性康复机构或辅助生活机构)。
共纳入93例患者进行分析;45例接受NE,42例接受EPI,6例接受DA。由于样本量小,事后分析中排除了DA的报告。在急诊科,达到难治性低血压、再次心脏骤停或死亡主要结局的EPI患者明显更多(EPI组21/42,50% vs. NE组10/45,22.2%;P = 0.008)。在6小时的早期复苏期,发生率不再有显著差异(EPI组30/42,71.4% vs. NE组25/45,55.6%;P = 0.182),在整个住院期间也无显著差异(EPI组40/42,95.2% vs. NE组36/45,80.0%;P = 0.051)。值得注意的是,EPI组在开始使用血管升压药之前再次心脏骤停的发生率更高,尽管其他预后变量分布相似,但这可能表明病情更严重。在一个调整回归模型中,该模型对开始使用血管升压药之前的再次心脏骤停进行了调整,与接受NE治疗的患者相比,EPI组在急诊科达到主要结局的几率高3.94[95%CI 1.38 - 12.2](P = 0.013)倍。两组之间在快速性心律失常或出院时的功能状态方面未检测到差异。
这些数据表明,对ROSC后用于血流动力学支持的初始血管升压药进行前瞻性研究可能是必要的。在该人群中,与接受去甲肾上腺素治疗的患者相比,接受肾上腺素治疗的患者急诊科内难治性休克、再次心脏骤停或死亡的发生率更高。然而,回顾性研究中无法控制潜在的混杂变量限制了研究结果。这些结果只是提出假设,需要进一步研究。